Prostate cancer is commonly treated with primary radiation therapy (RT), which results in similar long-term oncological outcomes as radical prostatectomy but with fewer patient-reported side-effects. Thanks to innovations in radiation techniques, at least 4 randomized trials could establish “moderate” hypofractionation (delivering 2.5-3.0 Gy per fraction over 4-5 weeks) as a new standard. Recently, “extreme” hypofractionation, typically delivering 4 to 5 fractions of 7 – 8 Gy once daily or every other day, was recognized as a valid alternative in selected patients. Arguably, such SBRT treatments will form the future of prostate cancer radiation therapy. First, we will discuss the current level of evidence and current indications, especially focusing on intermediate- and high-risk prostate cancer. Secondly, we will discuss differences in delineation both regarding target volumes (especially regarding the seminal vesicles) as well as organs at risk (OAR) and the use of margins. We will conclude with planning and image-guided delivery (fiducial markers, rectal spacers etcetera). This will be done in a very interactive way, with practical home-work sessions and individual feedback.